Zinc Protoporphyrin(Synonyms: 锌原卟啉; Zn(II)-protoporphyrin IX; ZnPP; Zinc Protoporphyrin-9)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Zinc Protoporphyrin (Synonyms: 锌原卟啉; Zn(II)-protoporphyrin IX; ZnPP; Zinc Protoporphyrin-9)

Zinc Protoporphyrin (Zn(II)-protoporphyrin IX) 是一种具有口服活性的，竞争性的血红素加氧酶-1 (HO-1) 抑制剂，显着减弱间苯三酚 (PG) 对 H2O2 的保护作用。Zinc Protoporphyrin 可用作个体孕妇和儿童缺铁的筛查标志物，也用于评估人群铁状态与血红蛋白浓度的组合。Zinc Protoporphyrin 具有抗癌活性。

Zinc Protoporphyrin(Synonyms: 锌原卟啉; Zn(II)-protoporphyrin IX; ZnPP; Zinc Protoporphyrin-9)

Zinc Protoporphyrin Chemical Structure

CAS No. : 15442-64-5

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥3512 In-stock
1 mg ￥650 In-stock
5 mg ￥2550 In-stock
10 mg ￥3750 In-stock
25 mg ￥7500 In-stock
50 mg ￥10500 询价
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

Zinc Protoporphyrin 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • Immunology/Inflammation Compound Library
  • Metabolism/Protease Compound Library
  • NF-κB Signaling Compound Library
  • Stem Cell Signaling Compound Library
  • Anti-Cancer Compound Library
  • Human Endogenous Metabolite Compound Library
  • Anti-Aging Compound Library
  • Antioxidants Compound Library
  • Oxygen Sensing Compound Library
  • Anti-Cardiovascular Disease Compound Library
  • Ferroptosis Compound Library
  • Pyroptosis Compound Library
  • Orally Active Compound Library
  • Mitochondria-Targeted Compound Library

生物活性

Zinc Protoporphyrin (Zn(II)-protoporphyrin IX) is an orally active and competitive heme oxygenase-1 (HO-1) inhibitor and markedly attenuates the protective effects of Phloroglucinol (PG) against H2O2[1]. Zinc Protoporphyrin is used as a screening marker of iron deficiency in individual pregnant women and children, but also to assess population iron status in combination with haemoglobin concentration[2]. Zinc Protoporphyrin has anti-cancer activity[3].

IC50 & Target[1][2]

Human Endogenous Metabolite

 

体外研究
(In Vitro)

Zinc Protoporphyrin (Zn(II)-protoporphyrin IX; 5 μM; 72 hours) causes the fraction of late apoptotic and necrotic cells increasing from 10.9% in controls to 30.4% after 72 h[3].
Zinc Protoporphyrin (1.25-40 μM; 48 or 72 hours) exerts cystostatic/cytotoxic effects against tumor cells[3].
Zinc Protoporphyrin (2.5, 5 μM; 48 or 72 hours) results in dose- and time-dependent reduction of cells in G1 phase of the cell cycle[3].
Zinc Protoporphyrin (1.25-40 μM; 48 hours) leads to accumulation of cleaved (active) caspase-3[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis[3]

Cell Line: C-26 cells
Concentration: 5 μM
Incubation Time: 72 hours
Result: The fraction of late apoptotic and necrotic cells increased from 10.9% in controls to 30.4% after 72 h.

Cell Cytotoxicity Assay[3]

Cell Line: C-26 and MDA-MB231 cells
Concentration: 1.25, 2.5, 5, 10, 20, 40 μM
Incubation Time: 48 or 72 hours
Result: Exerted cystostatic/cytotoxic effects against tumor cells.

Cell Cycle Analysis[3]

Cell Line: C-26 cells
Concentration: 2.5, 5 μM
Incubation Time: 48 or 72 hours
Result: Resulted in dose- and time-dependent reduction of cells in G1 phase of the cell cycle.

Western Blot Analysis[3]

Cell Line: C-26 cells
Concentration: 1.25, 2.5, 5, 10, 20, 40 μM
Incubation Time: 48 hours
Result: Leaded to accumulation of cleaved (active) caspase-3.

体内研究
(In Vivo)

Zinc Protoporphyrin (12.5, 25, 50 mg/kg for i.p.; 12.5, 50 mg/kg for p.o.; from day 7 to 19) exerts dose-dependent antitumor effects manifested by the retardation of tumor growth[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c mice inoculated with C-26 cells[3]
Dosage: 12.5, 25, 50 mg/kg for i.p.; 12.5, 50 mg/kg for p.o.
Administration: IP or PO; from day 7 to 19
Result: Exerted dose-dependent antitumor effects manifested by the retardation of tumor growth.

分子量

626.02

Formula

C34H32N4O4Zn
CAS 号

15442-64-5
中文名称

锌原卟啉
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

-20°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
溶解性数据
In Vitro: 

DMSO : 50 mg/mL (79.87 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.5974 mL 7.9870 mL 15.9739 mL
5 mM 0.3195 mL 1.5974 mL 3.1948 mL
10 mM 0.1597 mL 0.7987 mL 1.5974 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (3.99 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (3.99 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: 2.5 mg/mL (3.99 mM); Suspended solution; Need ultrasonic

    此方案可获得 2.5 mg/mL (3.99 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Park C, et al. Protective Effect of Phloroglucinol on Oxidative Stress-Induced DNA Damage and Apoptosisthrough Activation of the Nrf2/HO-1 Signaling Pathway in HaCaT Human Keratinocytes. Mar Drugs. 2019 Apr 13;17(4).

    [2]. Mwangi MN, et al. Diagnostic utility of zinc protoporphyrin to detect iron deficiency in Kenyan pregnant women. BMC Med. 2014 Nov 26;12:229.

    [3]. Nowis D, et al. Zinc protoporphyrin IX, a heme oxygenase-1 inhibitor, demonstrates potent antitumor effects but is unable to potentiate antitumor effects of chemotherapeutics in mice. BMC Cancer. 2008 Jul 11;8:197.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务